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ABSTRACT
Objective: To assess the nature and extent of physical-
health comorbidities in people with schizophrenia and
related psychoses compared with controls.
Design: Cross-sectional study.
Setting: 314 primary care practices in Scotland.
Participants: 9677 people with a primary care record
of schizophrenia or a related psychosis and 1 414 701
controls. Main outcome measures Primary care records
of 32 common chronic physical-health conditions and
combinations of one, two and three or more physical-
health comorbidities adjusted for age, gender and
deprivation status.
Results: Compared with controls, people with
schizophrenia were significantly more likely to have one
physical-health comorbidity (OR 1.21, 95% CI 1.16 to
1.27), two physical-health comorbidities (OR 1.37, 95%
CI 1.29 to 1.44) and three or more physical-health
comorbidities (OR 1.19, 95% CI 1.12 to 1.27). Rates
were highest for viral hepatitis (OR 3.98, 95% CI 2.81 to
5.64), constipation (OR 3.24, 95% CI 3.00 to 4.49) and
Parkinson’s disease (OR 3.07, 95% CI 2.42 to 3.88) but
people with schizophrenia had lower recorded rates of
cardiovascular disease, including atrial fibrillation (OR
0.62, 95% CI 0.51 to 0.73), hypertension (OR 0.71,
95% CI 0.67 to 0.76), coronary heart disease (OR 0.75,
95% CI 0.61 to 0.71) and peripheral vascular disease
(OR 0.83, 95% CI 0.71 to 0.97).
Conclusions: People with schizophrenia have a wide
range of comorbid and multiple physical-health conditions
but are less likely than people without schizophrenia to
have a primary care record of cardiovascular disease. This
suggests a systematic under-recognition and
undertreatment of cardiovascular disease in people with
schizophrenia, which might contribute to substantial
premature mortality observed within this patient group.
INTRODUCTION
Individuals with chronic-mental disorders
such as schizophrenia have increased stan-
dardised death rates compared with the
general population.1–4 On average, men with
schizophrenia die 20 years earlier and
women die 15 years earlier than people
without major mental illness.5 6 Although
death due to suicide is a contributing factor,
approximately two-thirds of this premature
ARTICLE SUMMARY
Article focus
▪ People with a diagnosis of schizophrenia are
known to be at high risk of poor physical-health
outcomes and premature mortality due to cardio-
vascular disease, diabetes, obesity and
smoking-related lung disease.
▪ The nature and extent of multiple physical-health
comorbidities within this patient group are
poorly understood.
▪ In a large primary care dataset of almost 1.8
million individuals, we assessed how patterns of
multiple physical-health comorbidities in schizo-
phrenia are influenced by age, gender and social
deprivation.
Key messages
▪ People with schizophrenia have a wide range of
multiple-comorbid physical-health problems
compared with people without schizophrenia,
even after controlling for the effects of age,
gender and social deprivation.
▪ Recorded rates were highest for viral hepatitis,
constipation and Parkinson’s disease but were
lower than expected for a number of cardiovas-
cular disorders, including atrial fibrillation, hyper-
tension, coronary heart disease and peripheral
vascular disease.
▪ This suggests a systematic under-recognition
and undertreatment of cardiovascular disease of
people with schizophrenia within primary care,
which might contribute to the substantial
cardiovascular-related morbidity and premature
mortality observed in this patient group.
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mortality are attributable to cardiovascular disease,
smoking-related lung disease and type II diabetes.4 6–8
Rates of smoking in schizophrenia are estimated at 70%
compared with 20% in the general population9, and at
least 10% of patients prescribed long-term antipsychotic
medications will develop type II diabetes, more than
twice the rate in the general population.10 There may
also be a shared genetic vulnerability between psychosis
and risk of diabetes.11
To date, there have been very few large-scale represen-
tative studies from primary care which assess the nature
and extent of physical-health comorbidity in people with
schizophrenia, as well as the inﬂuence of age, gender
and socioeconomic deprivation. Here, we examine the
range and number of the most common physical-health
comorbidities within a sample of 9677 people with a
recorded diagnosis of schizophrenia or a related psych-
osis, identiﬁed from a large Scottish primary care data-
base of almost 1.8 million individuals.12
METHODS
We used a dataset from the Primary Care Clinical
Informatics Unit at the University of Aberdeen which
consists of all 1 751 841 registered patients who were
alive and permanently registered with 314 general prac-
tices on 31 March 2007. This sample represents approxi-
mately one-third of the Scottish population. Data on the
presence of 32 of the most common chronic physical-
health conditions were extracted (listed in table A1).
A more detailed explanation on how these conditions
were selected and deﬁned is available elsewhere.12
People were identiﬁed as having ‘schizophrenia or
related non-organic psychosis’ (hereafter referred to
as ‘schizophrenia’) based on the recording ever of
any of the following primary care read codes (where
% is noted, this means ‘this code and any below it in
the code hierarchy’): E10% schizophrenic disorders;
E121 chronic paranoid psychosis; E12z paranoid
psychosis NOS; E13% other non-organic psychoses;
E13z non-organic psychosis/psychotic episode; NOS
E1z non-organic psychosis NOS; Eu20% schizophrenia;
Eu22% persistent delusional disorder or the recording
in the last 12 months of Eu23% acute/transient psych-
otic disorder. We restricted our analyses of this dataset
to individuals aged 18 and over and the sample was
divided into the following age groups for analysis: 18–24;
25–34; 35–44; 45–54; 55–64; 65–75 and 75 and over. Eight
individuals with schizophrenia who were under age 18
were excluded. Deprivation status was measured using
the Carstairs deprivation score which is widely used in
health research (divided into quintiles).13
Differences between those with schizophrenia (cases), all
other individuals (controls) and between female and male
individuals with schizophrenia were calculated by age,
deprivation and number of physical conditions. We used t
tests to analyse differences between groups and one-way
analysis of variance for differences across age groups and
deprivation quintiles. Logistic regression was used to calcu-
late ORs and 95% CIs in those with schizophrenia com-
pared with controls for the prevalence of all 32 physical
conditions, as well as no physical disorder, one comorbid
disorder and two or more comorbid disorders. OR calcula-
tions were adjusted for age, gender and deprivation score.
All analyses were performed in Stata V.11. The NHS
National Research Ethics Service approved the anonymous
use of these data for research purposes.
Results
Age, gender and deprivation status, schizophrenia versus
controls
We identiﬁed 9677 people with schizophrenia (0.7% of
the entire sample) and 1 414 701 controls (table 1).
Those with schizophrenia were more likely to be male
(schizophrenia 51.5% men vs controls 49.1% men;
p<0.001) and tended to be older than controls (schizo-
phrenia mean age 51.6 years vs controls mean age
48 years; p<0.001), although the magnitude of these dif-
ferences was small. Individuals with schizophrenia were
more socially deprived on average (schizophrenia
Carstairs score 0.34 vs controls −0.17; p<0.001), with
23.3% living in the most deprived quintile of postcodes
versus 17.8% of controls.
Physical-health comorbidity in people with schizophrenia
versus controls
Physical-health comorbidities were very common in people
with schizophrenia, even after adjusting for age, gender
and deprivation score. Compared with individuals without
schizophrenia, they were signiﬁcantly less likely to have no
recorded comorbidity (OR 0.61, 95% CI 0.58 to 0.64) and
signiﬁcantly more likely to have one comorbidity (OR 1.21,
95% CI 1.16 to 1.27), two comorbidities (OR 1.37, 95% CI
1.29 to 1.44) and three or more comorbidities (OR 1.19,
95% CI 1.12 to 1.27; table 2).
For each of the 32 individual physical conditions
assessed, prevalence was signiﬁcantly higher for people
with schizophrenia for 16 conditions, lower for 6 condi-
tions and with no difference for the remaining 10 condi-
tions (table 2 and ﬁgure 1). Prevalence was highest for
schizophrenia versus controls for viral hepatitis (OR
3.98, 95% CI 2.81 to 5.64), constipation (OR 3.24, 95%
CI 3.00 to 4.49) and Parkinson’s disease (OR 3.07, 95%
CI 2.42 to 3.88). People with schizophrenia also had
ARTICLE SUMMARY
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▪ The strengths of this study include the large representative
sample of almost 1.8 million individuals, of which almost
10 000 had a recorded diagnosis of schizophrenia or related
psychosis.
▪ The rate of a recorded diagnosis of schizophrenia or a related
psychotic disorder of 0.7% was slightly lower than might be
expected, with most estimates of the prevalence of schizo-
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higher rates of several important chronic health condi-
tions, including diabetes (9% in schizophrenia vs 5.2%
in controls; p<0.001), chronic obstructive pulmonary
disease (COPD; (6% vs 3.1%; p<0.001) and chronic pain
(13.8% vs 8.8%; p<0.001).
The most commonly diagnosed condition for indivi-
duals with schizophrenia was hypertension (16%),
although this rate was lower than in controls (16.5%). It
is also noteworthy that for the six conditions in which
the relative prevalence for schizophrenia patients was
lower, four were cardiovascular-related, including atrial
ﬁbrillation (OR 0.62, 95% CI 0.51 to 0.73), hypertension
(OR 0.71, 95% CI 0.67 to 0.76), coronary heart disease
(OR 0.75, 95% CI 0.61 to 0.71) and peripheral vascular
disease (OR 0.83, 95% CI 0.71 to 0.97).
Gender differences within the schizophrenia group
We assessed whether there might be differences between
men and women with schizophrenia in terms of the
number of recorded physical-health comorbidities, as
well as age and deprivation status (table 3). Physical
comorbidity was high in all schizophrenia patients, with
two-thirds of women and 50% of men having at least
one recorded comorbid physical condition (table 2).
Women with schizophrenia were signiﬁcantly more likely
to have two or more physical conditions (18.1% vs
12.9%; p<0.001) and three or more physical conditions
(23.9% vs 12.6%; p<0.001).
Discussion
In keeping with several recent reports, this study high-
lights that multiple physical-health comorbidity is a
major issue for people with schizophrenia and related
psychoses.1–4 6–8 14 15 A majority of people with
schizophrenia had at least one chronic physical comorbid-
ity and one-third had two or more. Compared with patients
without schizophrenia, patients with schizophrenia were
much more likely to have a primary care record of both
single and multiple physical-health problems, even after
taking into account age, gender and deprivation status. We
found three conditions to be particularly over-represented
in the schizophrenia group (viral hepatitis, constipation
and Parkinson’s disease), as well as high rates of diabetes,
chronic pain, epilepsy, COPD, dyspepsia, liver disease and
irritable bowel syndrome.
Under-recording of cardiovascular disease
Perhaps the most notable ﬁnding in this study was that
individuals with schizophrenia and related psychoses
had signiﬁcantly lower recorded rates of cardiovascular
disorders (including atrial ﬁbrillation, hypertension,
congestive heart disease and peripheral vascular disease)
than individuals without schizophrenia. This ﬁnding is
somewhat unexpected, given that several previous
studies have found high rates of cardiovascular morbid-
ity and mortality in schizophrenia.15 16 However, a
population-based study of administrative claims data in
the USA has found that rates of hypertension and
ischaemic heart disease were lower than expected in
individuals with schizophrenia compared with controls.14
Similarly, a recent meta-analysis of prescribing data for
patients with and without major mental illness (includ-
ing schizophrenia) found that those with severe mental
illness had much lower than expected rates of being pre-
scribed medications for cardiovascular disease.16 In a
recent Swedish national cohort study, people with inci-
dent schizophrenia were more likely to die prematurely
than the general population (15 years earlier for men
Table 1 Age, gender and deprivation status, schizophrenia versus controls
Variable
Schizophrenia Controls
Number (%) Number (%) Difference 95% CI (p<t)
Total 9677 (0.7) 1414701 (99.3)
Gender (% male) 4961 (51.5) 694468 (49.1) 2.4 (1.2 to 3.2) (p<0.001)
Age mean (SD) 51.6 (16.5) 48.0 (18.3) 3.6 (3.2 to 4.0) (p<0.001)
Deprivation mean (SD) 0.53 (3.5) −0.18 (3.3) 0.71 (0.64 to 0.77) (p<0.001)
Age group (years)
18–24 298 (3.1) 151395 (10.7) −7.6 (7.0 to 8.1) (p<0.001)
25–34 1216 (12.6) 228180 (16.1) −3.5 (2.8 to 4.3) (p<0.001)
35–44 2140 (22.1) 276853 (19.6) 2.5 (1.8 to 3.3) (p<0.001)
45–54 2079 (21.5) 251715 (17.8) 3.7 (2.9 to 4.5) (p<0.001)
55–64 1771 (18.3) 217562 (15.4) 2.9 (2.2 to 3.6) (p<0.001)
65–74 1094 (11.3) 154186 (10.9) 0.4 (−0,2 to 1.0) (p=0.20)
75 and over 1079 (11.2) 134810 (9.5) 1.7 (1.1 to 2.2 (p<0.001)
Deprivation quintile
1—Least deprived 1260 (13.0) 270769 (19.1) −6.1 (5.3 to 6.9) p<0.001)
2 1714 (17.7) 302440 (21.4) −3.1(2.8 to 4.5) (p<0.001)
3 2263 (23.4) 319984 (22.6) 0.8 (−0.0 to 1.6 (p=0.07))
4 2190 (22.6) 269194 (19.0) 3.6 (2.8 to 4.4) (p<0.001)
5—Most deprived 2250 (23.3) 252314 (17.8) 5.5 (4.7 to 6.2) (p<0.001)
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and 12 years earlier for women) and the leading causes
of death were cardiovascular disease and cancer.
However, in this study, the rates of recording of cardiovas-
cular disease and cancer were not much increased in
people with schizophrenia, even though these individuals
had more healthcare system contacts, suggesting that car-
diovascular disease and cancer are signiﬁcantly under-
diagnosed and/or under-recorded in this population.4
There may be several possible explanations for our
ﬁndings. People with schizophrenia may be less likely to
consult their general practitioner (GP) with symptoms
of cardiac or vascular disease because of low awareness
of cardiovascular risk and associated symptoms,17 or they
may be more likely to not have these areas investigated,
diagnosed18 and monitored.19 They might also expect
that their physical health needs are being met by their
community mental health teams.4 In general, rates of
consultation in individuals with major mental illness are
comparable to the general population20 but it is possible
that relatively asymptomatic conditions such as atrial ﬁb-
rillation are less likely to be identiﬁed than constipation,
irritable bowel syndrome, Parkinson’s disease, dyspepsia
and epilepsy. It is also possible that, even when these
patients do attend, GPs may not be assessing and/or
recording cardiac problems as often as they might with
patients who do not have schizophrenia.18 It is well
documented that patients with mental illness and
comorbid physical problems do not receive the same
level of assessment and treatment for their physical pro-
blems as patients without mental illness.21 22
Hypertension was the most common comorbidity
recorded within the schizophrenia group but was
Table 2 Prevalence and adjusted ORs for physical-health comorbidity (adjusted for age, gender and deprivation score)
Schizophrenia number
(%)
Controls number
(%) OR (95% CI)
No physical comorbidity 4069 (42.1) 796039 (56.3) 0.61 (0.58 to 0.64) (p<0.001)
One physical comorbidity 2363 (24.4) 290950 (20.6) 1.21 (1.16 to 1.27) (p<0.001)
Two physical comorbidities 1493 (15.4) 148231 (10.5) 1.37 (1.29 to 1.44) (p<0.001)
Three or more physical comorbidities 1752 (18.1) 179481 (12.7) 1.19 (1.12 to 1.27) (p<0.001)
Individual conditions
Viral hepatitis 33 (0.3) 1142 (0.1) 3.98 (2.81 to 5.64) (p<0.001)
Constipation 873 (9.0) 35543 (2.5) 3.24 (3.00 to 3.49) (p<0.001)
Parkinson’s disease 73 (0.8) 2668 (0.2) 3.07 (2.42 to 3.88) (p<0.001)
Epilepsy 213 (2.2) 12171 (0.9) 2.42 (2.11 to 2.77) (p<0.001)
Dyspepsia 1106 (11.4) 78098 (5.5) 1.92 (1.80 to 2.05) (p<0.001)
Liver disease 36 (0.4) 2578 (0.2) 1.66 (1.19 to 2.31) (p<0.001)
Irritable bowel syndrome (IBS) 540 (5.6) 51597 (3.7) 1.57 (1.44 to 1.72) (p<0.001)
Diabetes 870 (9.0) 73961 (5.2) 1.52 (1.40 to 1.64) (p<0.001)
Blindness 104 (1.1) 8274 (0.6) 1.44 (1.18 to 1.75) (p<0.001)
Thyroid disorders 738 (7.6) 71205 (5.0) 1.43 (1.32 to 1.54) (p<0.001)
Pain 1332 (13.8) 124799 (8.8) 1.39 (1.30 to 1.47) (p<0.001)
Psoriasis and eczema 101 (1.0) 10268 (0.7) 1.34 (1.10 to 1.63) (p<0.001)
Chronic obstructive pulmonary disease
(COPD)
577 (6.0) 52530 (3.1) 1.31 (1.20 to 1.43) (p<0.001)
Migraine 79 (0.8) 9172 (0.7) 1.27 (1.02 to 1.59) (p=0.03)
Asthma 696 (7.2) 83809 (5.9) 1.22 (1.12 to 1.31) (p<0.001)
Heart failure 167 (2.0) 18703 (1.3) 1.15 (0.99 to 1.32) (p=0.06)
Hearing loss 495 (5.1) 54239 (3.8) 1.14 (1.04 to 1.25) (p<0.001)
Sinusitis 69 (0.7) 9096 (0.6) 1.10 (0.86 to 1.34) (p=0.42)
Stroke and TIA 350 (3.6) 36195 (2.6) 1.07 (0.96 to 1.20) (p=0.19)
Crohn’s disease 71 (0.7) 9680 (0.7) 1.03 (0.81 to 1.33) (p=0.80)
Bronchiectasis 23 (0.2) 2791 (0.2) 0.99 (0.66 to 1.50) (p=0.99)
Diverticular disease 283 (2.9) 33530 (2.4) 0.96 (0.84 to 1.09) (p=0.61)
Chronic kidney disease 291 (3.0) 33275 (2.4) 0.95 (0.84 to 1.08) (p=0.48)
Glaucoma 123 (1.3) 15796 (1.2) 0.88 (0.73 to 1.04) (p=0.15)
Multiple sclerosis 23 (0.3) 3824 (0.3) 0.88 (0.59 to 1.33) (p=0.56)
Prostate disease 114 (1.2) 15119 (1.1) 0.86 (0.71 to 1.03) (p=0.11)
Peripheral vascular disease 167 (1.7) 23073 (1.6) 0.83 (0.71 to 0.97) (p=0.02)
Inflammatory arthritis 389 (4.0) 57619 (4.1) 0.82 (0.74 to 0.91) (p<0.001)
Cancer 288 (3.0) 43376 (3.1) 0.81 (0.72 to 0.91) (p<0.001)
Coronary heart disease 579 (5.9) 80888 (5.7) 0.75 (0.69 to 0.82) (p<0.001)
Hypertension 1551 (16.0) 232763 (16.5) 0.71 (0.67 to 0.76) (p<0.001)
Atrial fibrillation 137 (1.4) 23839 (1.7) 0.62 (0.51 to 0.73) (p<0.001)
TIA, transient ischaemic attack.
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signiﬁcantly less common than in the control group
(OR 0.71, 95% CI 0.67 to 0.76). It is possible that this
could be due to the use of antihypertensive agents for
symptoms such as anxiety or akathisia in the schizophre-
nia group or the hypotensive effect of some anti-
psychotic medications, but the most likely explanation in
our view would be less frequent monitoring of blood
pressure in primary care for patients with schizophrenia
relative to controls. Having said this, a recent systematic
review of features of metabolic syndrome in schizophre-
nia and related disorders found increased rates of hyper-
tension, so this is an area in need of more research.23
Although it will be important for our ﬁndings to be
replicated, this and other studies are consistent with a
systematic underdiagnosis of cardiovascular disease in
patients with schizophrenia, which, coupled with the
undertreatment of the diagnosed disease, may contrib-
ute to the high rates of cardiovascular morbidity and
premature mortality observed in this patient group.
Other medical comorbidities
Although difﬁcult to clarify within this dataset, it is pos-
sible to speculate on the reasons for the high rates of
viral hepatitis, constipation and Parkinson’s disease
Table 3 Differences between women and men with schizophrenia
Variable Women Men
Number (%) Number (%) Difference 95% CI (p<t)
Total 4716 (48.7) 4961 (51.3)
Age mean (SD) 55.6 (17.0) 47.8 (15.2) 7.8 (7.2 to 8.4) (p<0.001)
Deprivation mean (SD) 0.29 (3.4) 0.77 (3.5) −0.5 (−0.34 to −0.68) (p<0.001)
Age group (years)
18–24 102 (2.2) 196 (4.0) −1.8 (−1.1 to −2.4) (p<0.001)
25–34 400 (8.5) 816 (16.5) −8.0 (6.7 to 9.2) (p<0.001)
35–44 865 (18.3) 1275 (25.7) −7.4 (−5.7 to −9.0) (p<0.001)
45–54 968 (20.5) 1111 (22.4) −1.9 (−0.2 to −3.5) (p=0.03)
55–64 935 (19.8) 836 (16.9) 2.9 (1.4 to 4.5) (p<0.001)
65–74 663 (14.1) 431 (8.7) 5.4 (4.1 to 6.6) (p<0.001)
75 and over 783 (16.6) 296 (6.0) 10.6 (9.9 to 11.3) (p<0.001)
Deprivation quintile Difference 95% CI (p<t)
1—Least deprived 678 (14.4) 582 (11.7) 2.6 (1.3 to 3.9) (p<0.001)
2 862 (18.3) 852 (17.2) 1.1 (−0.4 to 2.0) (p=0.15)
3 1146 (24.3) 1117 (22.5) 1.8 (0.0 to 3.4 (p=0.04)
4 1060 (22.5) 1130 (22.8) −0.3 (−1.9 to 0.3) (p=0.26)
5—Most deprived 970 (20.6) 1280 (25.8) −5.2 (−3.6 to −6.9) (p<0.001)
Number of comorbidities
No physical 1577 (33.4) 2492 (50.2) − 16.8 (−14.9 to 3.9) (p<0.001)
One physical 1155 (24.5) 1208 (24.4) 0.1 (−1.5 to 1.8) (p=0.87)
Two physical 855 (18.1) 638 (12.9) 5.2 (3.8 to 6.7) (p<0.001)
Three or more 1129 (23.9) 623 (12.6) 11.3 (9.8 to 12.9) (p<0.001)
Figure 1 ORs for individual
physical-health comorbidities,
schizophrenia versus controls
(adjusted for age, gender and
deprivation status).
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within the schizophrenia group. For example, this
sample (which comprised ‘schizophrenia and related
psychoses’) is likely to include a proportion of people
with a history of drug misuse who will be at higher risk
of viral hepatitis. It is possible that this has contributed
to the higher recorded rates of viral hepatitis within the
schizophrenia group.
Constipation is an important though often neglected
side effect of antipsychotic medication,24 25 and it is of
interest that it was much more commonly recorded in
the schizophrenia group than in controls. However,
most estimates suggest that between 20% and 30% of all
patients taking antipsychotic medications will have con-
stipation.25 The prevalence of 9% within the schizophre-
nia group in our study is therefore likely to be an
underestimate of the true ﬁgure.
Although relatively rarely recorded, Parkinson’s
disease was signiﬁcantly more common in the schizo-
phrenia group than in controls (0.8% vs 0.2%, OR 3.07,
95% CI 2.42 to 3.88) and could also represent a
common extrapyramidal side effect of antipsychotic
medication.
Gender differences
We found that patients with schizophrenia (and particu-
larly men) were over-represented in areas of higher
social deprivation. It is well documented that socio-
economic disadvantage and urban residence contribute
to the risk of developing a psychotic disorder,26 but the
cross-sectional nature of our data make it difﬁcult to
assess whether our ﬁnding is due to this or is a conse-
quence of social drift. Additionally, we found that
women with schizophrenia were more likely than men
with schizophrenia to have multiple comorbidities—this
gender difference was also observed in the Swedish
national cohort study noted above.4 In our dataset, it
might be explained by the fact that women with schizo-
phrenia were older on average than men with schizo-
phrenia (possibly due to the greater premature
mortality for men) and the possibility that women are
more likely to consult with their GP than men.27 Future
work should seek to explore these gender differences in
more detail, for example, by assessing the help-seeking
behaviours of men and women with schizophrenia and
how these behaviours are inﬂuenced by age and socio-
economic background.
Strengths and limitations
The strengths of this study include the large sample size
(almost 1.8 million individuals), which is representative
of the Scottish population, but some potential limita-
tions should be noted. The rate of a recorded diagnosis
of schizophrenia or a related psychotic disorder of 0.7%
could be considered to be lower than expected, with
most estimates of the prevalence of schizophrenia
around 1%,28 although it is recognised that estimates of
the incidence and prevalence of schizophrenia can be
subject to wide variations across different locations
because of the differences in population characteristics,
exposure levels and diagnostic assessment.28 It is possible
that some patients with schizophrenia or a related psych-
otic disorder are known to secondary care services but
are not recorded within primary care and that a small
additional proportion may not be in contact with either
primary or secondary care. Further, these are routine
data from 314 primary care practices and there may be
some variability of diagnostic coding for major mental
illnesses across these practices. Conversely, it is possible
that in addition to the under-recognition and under-
recording of cardiovascular disease in patients with
schizophrenia, some of the prevalence rates for other
physical-health comorbidities may be underestimated.
Conclusions
Overall, this study highlights that people with schizo-
phrenia have high rates of multiple comorbid physical
health problems, emphasising the importance of an
integrated approach to their care.29 30 It is well docu-
mented that physical and mental health problems inter-
act to cause prolonged hospitalisation, treatment failure,
poor quality of life and premature mortality.15 17 31 The
current separation between specialist physical and
mental health services, and between primary and sec-
ondary care services in the UK and other countries,
makes the co-ordinated care of the physical health of
patients with schizophrenia difﬁcult. Several recent
reports have highlighted that more integrated services
are needed but how best to achieve this is currently
unclear.32–35 This issue may be particularly relevant for
cardiac disease because, although many studies have
found that patients with schizophrenia have high rates
of cardiovascular morbidity and mortality, our ﬁndings
and other recent evidence suggest that they have lower
than expected rates of being diagnosed with and treated
for cardiovascular disorders.
Integrated care requires the delivery of preventive and
curative health services which vary according to individ-
ual needs over time and across different levels of the
healthcare system and can be difﬁcult to achieve. Given
that cardiovascular risk assessment has been shown to be
acceptable to many people with psychosis,36 a more sys-
tematic use of such screening in both primary and sec-
ondary care may improve early detection and treatment
of hypertension, hypercholesterolaemia, diabetes and
smoking. Further research is needed to evaluate the
effectiveness of such approaches to improve the physical
health and life expectancy of people with schizophrenia.
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APPENDIX
Table A1 Definitions of 32 physical-health conditions assessed
Condition Variable name Variable definition
Coronary heart disease CHD Read code ever recorded
Chronic kidney disease CKD Read code ever recorded
Asthma (active) Asthma Read code ever recorded AND any prescription in the
previous year
Atrial fibrillation Atrial fibrillation Read code ever recorded
Epilepsy Epilepsy Read code ever recorded AND epilepsy prescription in
the previous year
New cancer in the last 5 years Cancer Read code first recorded in the last 5 years (Relevant
Read Code recorded)
Thyrotoxicosis/thyroid disorders (includes
hypothyroidism)
Thyroid disorders Read code ever recorded (Relevant Read Code
recorded)
Diabetes Diabetes Read code ever recorded
Parkinson’s disease Parkinson’s
disease
Read code ever recorded (Relevant Read Code
recorded)
Multiple sclerosis Multiple sclerosis Read code ever recorded (Relevant Read Code
recorded)
Stroke or transient ischaemic attack Stroke or TIA Read code ever recorded (Relevant Read Code
recorded)
Blindness and low vision Blindness Read code ever recorded (Relevant Read Code
recorded)
Glaucoma Glaucoma Read code ever recorded (Relevant Read Code
recorded)
Hearing loss Hearing loss Read code ever recorded (Relevant Read Code
recorded)
Hypertension Hypertension Read code ever recorded (Relevant Read Code
recorded)
Heart failure Heart failure Read code ever recorded
Peripheral vascular diseases PVD Read code ever recorded (Relevant Read Code
recorded)
Chronic sinusitis Sinusitis Read code ever recorded (Relevant Read Code
recorded)
Bronchitis, emphysema & other chronic
obstructive pulmonary diseases
COPD Read code ever recorded (Relevant Read Code
recorded)
Bronchiectasis Bronchiectasis Read code ever recorded (Relevant Read Code
recorded)
Crohn’s disease and ulcerative colitis Inflammatory
bowel disease
Read code ever recorded (Relevant Read Code
recorded)
Diverticular disease of the intestine Diverticular
disease
Read code ever recorded (Relevant Read Code
recorded)
Rheumatoid arthritis, other inflammatory
polyarthropathies and systematic connective
tissue disorders
Inflammatory
arthritis
Read code ever recorded (Relevant Read Code
recorded)
Hyperplasia of prostate and prostate disorders Prostate disease Read code ever recorded (Relevant Read Code
recorded)
Psoriasis or eczema Psoriasis/eczema Read code ever recorded (M11% & M12%) AND ≥ 4
prescription in last year (BNF 13.4, excluding
hydrocortisone and BNF 13.5)
Viral hepatitis Viral hepatitis Read code ever recorded (Relevant Read Code
recorded)
Irritable bowel syndrome Irritable bowel
syndrome
Read code ever recorded (Relevant Read Code
recorded) OR ≥ 4 antispasmodic prescription in the
previous year (POM only, exclude kolanticon, alverine
citrate and peppermint oil)
Continued
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Table A1 Continued
Condition Variable name Variable definition
Cirrhosis/chronic liver disease/alcoholic liver
disease
Chronic liver
disease
Read code ever recorded (Relevant Read Code
recorded)
Migraine Migraine ≥ 4 anti-migraine prescriptions in last year (BNF
040704%, POM only exclude migraleve)
Dyspepsia Dyspepsia ≥ 4 prescriptions in last year BNF 0103% excluding
antacids AND NOT ≥4 NSAIDS OR ≥4 aspirin/
clopidogrel
Constipation Constipation ≥4 prescriptions in last year, BNF 0106%
pain pain ≥4 specified analgesic prescriptions in the previous
year (opioids/>8 mg cocodamol/NSAIDS) OR ≥4
specified antiepileptics in the absence of an epilepsy
Read code in last year (gabapentin, pregabalin and
carbamazepine)
BNF, British National Formulary; NSAIDS, non-steroidal anti-inflammatory drugs; POM, prescription only medicine.
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